Avalo Therapeutics Purchases Optional Milestone Buyout
Rhea-AI Summary
Avalo Therapeutics (Nasdaq: AVTX) entered a Milestone Buyout Option and Amendment Agreement related to its March 2024 acquisition of AlmataBio. Avalo paid $2.25 million for an option, exercisable within 90 days, to pay an additional $5.125 million in cash, stock, or combination.
If exercised, that payment replaces a previously disclosed $15 million contingent milestone tied to first patient dosing in a Phase 3 trial.
AI-generated analysis. Not financial advice.
Positive
- Liability reduced from $15M contingent to potential $5.125M
- Option provides certainty with a defined 90-day decision window
- Flexible payment choice of cash, stock, or combination
Negative
- Immediate cash outflow of $2.25M
- Potential dilution if $5.125M paid in Avalo common stock
News Market Reaction – AVTX
On the day this news was published, AVTX declined 10.82%, reflecting a significant negative market reaction. Argus tracked a trough of -16.1% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $49M from the company's valuation, bringing the market cap to $402.32M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, AVTX showed a 3.59% move with mixed peer action: ZURA up 0.56%, AGEN up 3.02%, CYBN up 0.12%, while ACTU fell 4.52% and GLSI was flat. Momentum scanner flags ZURA up 2.96% and ACTU down 8.42%, indicating stock-specific rather than a clean sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Earnings and update | Neutral | +0.6% | 2025 financials and cash runway into 2028 with higher R&D spending. |
| Feb 24 | Investor conferences | Positive | +9.5% | Participation in March 2026 healthcare investor conferences with webcasts. |
| Feb 18 | Inducement grants | Neutral | +6.5% | Inducement stock options for new employees under Nasdaq Listing Rule 5635(c)(4). |
| Feb 04 | Investor conferences | Neutral | -10.0% | February 2026 conference participation announcement with webcast availability. |
| Nov 17 | Inducement grants | Neutral | +6.7% | Multiple stock option inducement grants to new hires under 2025 plan. |
Recent AVTX news has more often coincided with positive price reactions, with only one notable negative move on a neutral conference update.
Over the last six months, Avalo’s news flow has focused on financial updates, investor outreach, and equity-based compensation. The Mar 23, 2026 earnings release highlighted $98.3M in cash funding operations into 2028 and higher 2025 R&D and net loss. Multiple conference participation announcements in Feb–Mar 2026 and recurring inducement option grants have generally seen modestly positive to strongly positive price reactions, aside from one negative move after a February conference update. Today’s transaction news fits into this pattern of balance-sheet and strategic housekeeping updates.
Regulatory & Risk Context
An effective S-3 shelf dated 2026-01-08 allows Avalo to offer up to $750,000,000 in various securities, with $326,585,963 carried forward from a prior shelf and usage_count at 0. This provides significant flexibility to raise capital for clinical trials, R&D, and corporate purposes as needed.
Market Pulse Summary
The stock dropped -10.8% in the session following this news. A negative reaction despite a restructuring of milestone terms could reflect concern over near-term cash usage or future dilution rather than the economics alone. The company agreed to a $2.25 million payment plus an option for an additional $5.125 million in cash or stock, altering the prior $15 million contingent Phase 3 milestone. With an effective $750,000,000 shelf available, traders may have focused on the possibility of equity issuance even as Avalo manages legacy acquisition commitments.
Key Terms
milestone buyout option financial
contingent milestone payment financial
phase 3 trial medical
AI-generated analysis. Not financial advice.
WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the “Buyout Agreement”) related to the company’s prior acquisition of AlmataBio, Inc. in March of 2024.
Pursuant to the Buyout Agreement, Avalo has agreed to pay
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, abdakibart (AVTX-009), is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
